HOMEwww.epgonline.orgDRUGSwww.epgonline.orgDISEASE KNOWLEDGEwww.epgonline.orgGUIDELINESwww.epgonline.orgCLINICAL TRIALSwww.epgonline.orgREGISTERwww.epgonline.orgSEARCH
Members
Why a doctor should
Username/Email

Password ()




EPG on Twitter EPG Online Twitter
EPG Online Blog EPG Online Blog
EPG Online Disease Knowledge Centres Feed Disease Knowledge
Recent UK Drug Updates Drug Updates
EPG Search
Search
Languages

Social Networks
Drug Updates
The prognosis of patients with diabetes is improved by interventions that reduce HbA1C Chronic Kidney Disease (CKD) is characterised by a gradual and permanent loss of kidney function that worsens as it progresses from stages 1 to 5. One of the most common complications of CKD is anaemia. Alzheimer's disease (AD) is a progressive, neurodegenerative disease which will affect most of us at one point in time, and it’s prevalence increases with age. Parkinson's disease (PD) is a degenerative disorder of the central nervous system characterized by the clinically asymmetric onset of resting tremor, bradykinesia, rigidity and postural instability.
EPG Online Clinical Trials by Area
Area | Source | Year Finished Order: A to Z - Z to A

Acne

ADHD

Alzheimer’s Disease

  • A Double-Blind, Randomized, Placebo-Controlled, Comparative Study of Celecoxib (SC-58635) For the Inhibition of Progression of Alzheimer’s Disease

    Clinicalstudyresults.org (Jun 1999)

    The primary objectives were to: • Assess whether treatment with celecoxib 200 mg twice daily (BID) would statistically significantly limit or attenuate the progression of Alzheimer’s Disease as measured by the change in the Alzheimer’s Disease Assessment Scale-Cognitive Behavior (ADAS-Cog) composite score and the Clinician’s Interview-Based Impression of Change Plus (CIBICPlus) score • Evaluate the safety of celecoxib at 200 mg BID in the elderly population suffering from Alzheimer’s Disease during long-term treatment The secondary objectives were to: • Evaluate the change from Baseline after one year of treatment in the Behavioral Pathology in Alzheimer’s Disease (Behave-AD) score, the Nurses Observation Scale for Geriatric Patients (NOSGER) score, the scores for the recall and recognition scales of the ADAS, the Mini-Mental State Exam (MMSE) score, and the scores of the Pharmacoeconomic (PE) and Quality of Life surveys (QOL) [SF-36] • Additional assessments included the Montgomery-Asbers Depression Rating Scale (MADRS) to confirm that depression was not playing an interfering role

Anemia

Arthritis

Asthma

Back Pain

Bladder cancer

  • Electrically-stimulated intravesical chemotherapy for superficial bladder cancer

    Clinicaltrials.gov (Jan 2008)

    This procedure, also known as electromotive drug administration (EMDA) of intravesical chemotherapy, can be used for patients with bladder cancer, either before or after surgery. A solution including a chemotherapy drug is injected into the bladder using a thin tube inserted through the urethra. At the same time, an electrode is inserted in the bladder and other electrodes are placed on the skin of the lower abdomen. An electric current is then created with the aim of improving absorption of the chemotherapeutic drugs.

Bone Cancer

Brain cancer

  • Palliative Radiation Extends Survival for Elderly Patients with Glioblastoma

    National Cancer Institute (Mar 2007)

    The investigators enrolled 81 patients 70 years of age or older with glioblastoma into the trial. All patients had good functional status. Forty-two received supportive care alone, including antiseizure medication, physical and psychological support, and access to a palliative care team. The other 39 patients received supportive care and radiation therapy (50 Gy in doses of 1.8 Gy per day, given 5 days a week).

Breast Cancer

Cervical Cancer

Chronic Kidney disease

  • Early identification and management of chronic kidney disease in adults in primary and secondary care

    NICE (Jan 2008)

    The advice in the NICE guideline covers: * the tests doctors should use to diagnose long-term kidney problems (chronic kidney disease) * the best treatment and care for adults diagnosed with chronic kidney disease, and when they should be referred to specialist renal services * the general management of chronic kidney disease from a variety of causes including diabetes, high blood pressure and cardiovascular disease.

CML

  • Registration of Children With CML and Treatment With Imatinib (CML-paed II)

    Clinicaltrials.gov (Jan 2012)

    Newly diagnosed pediatric patients (age < 19 years) with bcr-abl-positive CML will be treated with imatinib. Serial monitoring of treatment response is performed in one month intervals during the first three months of treatment and in three months intervals thereafter. Patients with non-response, poor response (either molecular, cytogenetic, or hematologic non-/poor response) or progress of the disease while under imatinib treatment will stop imatinib and undergo stem cell transplantation. All responders to imatinib treatment with an HLA matched donor will undergo stem cell transplantation not later than 2 years after diagnosis.

Colon Cancer

Colorectal Cancer

Congestive Heart Failure

Diabetes

  • Continuous subcutaneous insulin infusion for the treatment of diabetes (review)

    Clinicaltrials.gov (Jan 2008)

    This guidance replaces NICE technology appraisal guidance 57 issued in February 2003. The review and re-appraisal of the use of continuous subcutaneous insulin infusion for the treatment of diabetes mellitus has resulted in a change in the guidance. Specifically there has been a change to the recommendation on the use of continuous subcutaneous insulin infusion in children younger than 12 years with type 1 diabetes mellitus.

  • Diabetes in pregnancy: management of diabetes and its complications from pre-conception to the postnatal period

    Clinicaltrials.gov (Jan 2008)

    This guidance covers the care and treatment of pregnant women with diabetes in the NHS in England and Wales. It also covers the care of their newborn babies. It is written for women who have diabetes or develop it in pregnancy, but it may also be useful for their families or for anyone with an interest in the condition. July 2008: Since publication, the information on the therapeutic indications, contraindications and use in pregnancy and lactation of drugs used in diabetes management and retinal assessment (specifically insulins, the oral hypoglycaemic agents metformin and glibenclamide, and tropicamide) has been corrected to follow the relevant summaries of product characteristics (SPCs) (July 2008). Changes have been made to the NICE guideline, the full guideline and the quick reference guide. 'The recommendation on the use of the rapid-acting insulin analogues aspart and lispro in pregnant women with diabetes (this is recommendation 1.1.6.2 in the NICE guideline) is now as follows: Healthcare professionals should be aware that data from clinical trials and other sources do not suggest that the rapid-acting insulin analogues (aspart and lispro) adversely affect the pregnancy or the health of the fetus or newborn baby

Diabetes Type 1

Diabetes Type 2

Drug Interaction Study

Eczema

Epilepsy

Esophageal Cancer

Fungal infection

GERD

Gout

Head and Neck Cancer

Heart Failure

Hepatitis B

  • A Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Eplerenone in Patients With Heart Failure Following Acute Myocardial Infarction (EPHESUS).

    Clinicalstudyresults.org (Dec 2002)

    Primary: The primary objectives of this study were to compare the effect of eplerenone plus standard therapy versus placebo plus standard therapy on (1) the rate of all cause mortality and (2) the rate of cardiovascular (CV) mortality/CV hospitalization. CV hospitalization was defined as hospitalization for heart failure [HF], recurrent acute myocardial infarction [AMI], stroke, or ventricular arrhythmia, while CV mortality/CV morbidity was defined as the time to first occurrence of either CV death or CV hospitalization, in patients with HF after AMI. All cause mortality was defined as any mortality adjudicated as follows: CV mortality (defined as sudden cardiac death, recurrent AMI, HF, stroke or other CV mortality, including aneurysm or pulmonary embolism); non-CV mortality (including sepsis, pneumonia, cancer, and other non- CV mortality); unwitnessed death or unknown reason for death. Secondary: The secondary objectives of this study were to compare the 2 treatment groups for the following: time to CV mortality (as previously described); all cause mortality/hospitalization; and CV mortality/nonfatal AMI. All cause hospitalization was defined as: CV hospitalizations; hospitalizations for other CV reasons (defined as: atrial flutter, atrial fibrillation, supraventricular tachycardia; angina [stable or unstable]; other CV hospitalizations, including peripheral vascular disease, hypotension, elective CV surgery, or other CV procedures; non-CV hospitalizations [defined as: pneumonia;

  • A Phase II Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-infected Patients Who Have Hepatitis B Viremia While on Lamivudine Treatment

    Clinicalstudyresults.org (May 2004)

    The hypothesis of this study is that adding entecavir 1.0 mg to lamivudine will be superior to adding placebo to lamivudine in reducing HBV DNA levels from baseline in HIV/HBV co-infected subjects who had experienced recurrence of HBV viremia on a lamivudine-containing HAART regimen.

  • Clinical Protocol for an Open-Label Extension Study Evaluating the Safety of Eplerenone in Patients with Heart Failure

    Clinicalstudyresults.org (Feb 2007)

    This open-label extension study was performed as a statistically significant difference favoring eplerenone over placebo for both of the primary endpoints was reported in Eplerenone Post-Acute Myocardial Infarction (AMI) Heart Failure Efficacy and Survival Study (EPHESUS). The objective of this open-label extension study was to provide eplerenone to subjects who did not permanently discontinue study medication during the EPHESUS Study or EPHESUS Double-Blind Extension. All subjects in the open-label extension study were to receive eplerenone until the drug was commercially available for the heart failure indication in the respective country, but no longer than 30 months (36 months for selected sites in Israel) after the first visit of the open-label extension study or until other plans were made by the sponsor to supply drug.

  • Entecavir for the treatment of chronic hepatitis B

    Clinicaltrials.gov (Jan 2008)

    Entecavir is recommended as a possible treatment for people with chronic hepatitis B.

  • Telbivudine for the treatment of chronic hepatitis B

    NICE (Jan 2008)

    Telbivudine is not recommended for people with chronic hepatitis B. Healthcare professionals should not stop prescribing telbivudine for people who were already taking it when the guidance was issued.These patients should be able to carry on taking telbivudine until they and their healthcareprofessionals decide that it is the right time to stop treatment.

Hepatitis B, Chronic

Hepatitis C

  • A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C

    Centerwatch (Jan 2009)

    This study will evaluate the safety and tolerability of interferon alfa-2a in combination with ribavirin in patients with chronic hepatitis C. Patients who have never received prior interferon therapy, and patients who have relapsed after prior interferon therapy, will be eligible for this trial. the anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals. Target sample size is 5000.

  • An Open Phase II Pilot Study to Determine the Safety and Activity of Lamivudine in Patients with Chronic Hepatitis C Infection

    Clinicalstudyresults.org (Dec 1995)

    Chronic hepatitis C is a significant cause of morbidity and mortality in man. An effective, well tolerated treatment for this disease is highly desirable. The absence of reliable in vitro and in vivo models to predict the activity of lamivudine against the hepatitis C virus justifies this study in man. Lamivudine has been studied in subjects with HIV and chronic hepatitis B infection, and has shown significant activity. These results do not preclude a small pilot study in subjects with chronic hepatitis C infection.

HIV

HIV Infections

Hodgkin Lymphoma

  • Lower-Toxicity Treatment Effective in Some Cases of Early-Stage Hodgkin's Lymphoma

    National Cancer Institute (Jul 2006)

    An experimental low-intensity four-drug chemotherapy regimen plus limited radiation therapy improved cancer-free survival in patients with early-stage Hodgkin’s lymphoma who had a favorable outlook. However, patients with an unfavorable outlook did better with standard six-drug chemotherapy plus limited radiation therapy.

  • PET Can Strongly Predict Likelihood of Early Relapse in Hodgkin Lymphoma

    National Cancer Institute (Aug 2007)

    positron emission tomography (PET) scan taken after two cycles of standard chemotherapy in patients with advanced Hodgkin lymphoma was able to predict with 92-percent accuracy how effective a complete course of the chemotherapy would be. The PET scan was able to distinguish between patients who would achieve long-term control of their disease and patients whose disease would progress during treatment or immediately thereafter or would later relapse. This procedure can be used to identify Hodgkin lymphoma patients who might benefit from a switch to more-intensive chemotherapy.

Hypertension

Influenza

Irritable bowel symdrome

  • Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care

    Clinicaltrials.gov (Jan 2008)

    "The advice in the NICE guideline covers the care of adults with irritable bowel syndrome, including: *the support, treatment and advice people should be offered by their GP in diagnosing and helping to manage their irritable bowel syndrome *circumstances when people need to be referred to a specialist for further tests. It does not specifically look at: *irritable bowel syndrome in children and young people under 18 years *people with other gastrointestinal disorders such as non-ulcer dyspepsia (indigestion with no obvious cause) or coeliac disease. "

  • Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care

    Clinicaltrials.gov (Jan 2008)

    The advice in the NICE guideline covers the care of adults with irritable bowel syndrome, including: * the support, treatment and advice people should be offered by their GP in diagnosing and helping to manage their irritable bowel syndrome * circumstances when people need to be referred to a specialist for further tests. It does not specifically look at: * irritable bowel syndrome in children and young people under 18 years * people with other gastrointestinal disorders such as non-ulcer dyspepsia (indigestion with no obvious cause) or coeliac disease.

Kidney Cancer

Kidney Disease

Kidney Transplantation

Leukemia

Liver Cancer

Lung Cancer

  • Cisplatin-Based Chemotherapy Improves Survival in Non-Small Cell Lung Cancer

    National Cancer Institute (Jun 2006)

    Combined data from five large randomized clinical trials confirmed that cisplatin-based chemotherapy extends survival for patients with stage II or stage III non-small cell lung cancer. The benefit did not differ with different chemotherapy regimens, and was not affected by variables such as age, gender, or tumor type.

  • Elderly Benefit From Chemotherapy After Surgery for Early Non-Small Cell Lung Cancer

    National Cancer Institute (Jun 2006)

    Elderly patients with early-stage non-small cell lung cancer who received chemotherapy following surgery lived longer than those who’d had surgery alone, without an increase in treatment-related toxicity or hospitalization. These results provide more evidence that chemotherapy should not be withheld from elderly patients on the basis of age alone

  • Erlotinib (Tarceva®) Extends Survival in Advanced Lung Cancer

    National Cancer Institute (Jul 2005)

    Erlotinib (Tarceva®) prolonged survival in patients with advanced non-small cell lung cancer who had progressed after standard chemotherapy

  • Erlotinib for the treatment of non-small cell lung cancer

    NICE (Jan 2008)

    Erlotinib is recommended as an alternative to docetaxel for patients with non-small-cell lung cancer (NSCLC) who have already tried one chemotherapy regimen but it has not worked. Erlotinib should be used only when the manufacturer provides the drug at the same overall treatment cost as docetaxel. This cost includes the cost of giving the drug, treatments for any side effects and the cost of monitoring patients to check that treatment is working. If the overall treatment cost is equal, specialists should discuss with patients the potential benefits and risks of erlotinib and docetaxel before deciding which treatment to use. Erlotinib is not recommended for people with locally advanced or metastatic NSCLC who cannot take docetaxel and have already tried one chemotherapy regimen but it has not worked. Erlotinib is not recommended for people who have already tried two chemotherapy regimens, including docetaxel, but they haven't worked.

  • Lung cancer: diagnosis and treatment

    NICE (Jan 2005)

    The NICE lung cancer clinical guideline covers the full range of care that should be available from the NHS to adults who have lung cancer, or whose doctors think they may have lung cancer. They include how the diagnosis should be made and the treatments that should be offered at different times.

  • Radiotherapy Can Prevent Spread of Small-Cell Lung Cancer to the Brain

    National Cancer Institute (Jun 2007)

    Radiation therapy to the head, given to patients who had responded to chemotherapy for advanced small-cell lung cancer, reduced by about two-thirds the risk that patients’ tumors would spread to the brain, thus extending patients’ lives. These findings are likely to change the standard of care for this group of patients.

  • Sorafenib Increases the Risk of High Blood Pressure

    National Cancer Institute (Feb 2008)

    Combined data from nine studies showed that patients receiving the standard amount of sorafenib (Nexavar), an anticancer drug that interferes with a tumor’s blood supply, run a significant risk of high blood pressure (hypertension). Doctors should closely monitor these patients during treatment and prescribe anti-hypertension drugs as needed.

  • Whole Brain Radiation May be Postponed in Cancer Patients with Limited Metastasis to the Brain

    National Cancer Institute (Jun 2006)

    Patients who received stereotactic radiosurgery for four or fewer contained metastases to the brain lived as long, and had comparable radiation side effects and mental functioning, as patients who were also treated with whole brain radiation. However, the radiosurgery-only patients had higher recurrence in their brain and were more likely to require salvage treatment.

Major Depressive Disorder

Multiple Myeloma

Non-Hodgkin's Lymphoma

Non-Small Cell Lung Cancer

  • A randomized double-blind multicenter phase III study of bevacizumab in combination with cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer, who have not received prior chemotherapy.

    Roche: Clinical Trials (Jan 2007)

    This was a multi-center, randomized, double-blind study to investigate the effect of adding two different doses of Avastin (bevacizumab) to cisplatin and gemcitabine on progression-free survival in patients with advanced or recurrent non-squamous non-small cell lung cancer.

  • Erlotinib for the treatment of non-small cell lung cancer

    Clinicaltrials.gov (Nov 2008)

    Erlotinib is recommended as an alternative to docetaxel for patients with non-small-cell lung cancer (NSCLC) who have already tried one chemotherapy regimen but it has not worked. Erlotinib should be used only when the manufacturer provides the drug at the same overall treatment cost as docetaxel. This cost includes the cost of giving the drug, treatments for any side effects and the cost of monitoring patients to check that treatment is working. If the overall treatment cost is equal, specialists should discuss with patients the potential benefits and risks of erlotinib and docetaxel before deciding which treatment to use. Erlotinib is not recommended for people with locally advanced or metastatic NSCLC who cannot take docetaxel and have already tried one chemotherapy regimen but it has not worked. Erlotinib is not recommended for people who have already tried two chemotherapy regimens, including docetaxel, but they haven't worked. Healthcare professionals should not stop prescribing erlotinib for people who were already taking it when the guidance was issued. These patients should be able to carry on taking erlotinib until they and their specialist decide that it is the right time to stop treatment.

Obesity

Osteoarthritis

  • The care and management of osteoarthritis in adults

    Clinicaltrials.gov (Jan 2008)

    The advice in the NICE guideline covers the treatment, advice and support that people who have osteoarthritis should be offered by their healthcare professional and when being referred to specialist care. This includes: * diagnosis * education * exercise and physiotherapy * medicines * alternative therapies * surgery. It does not specifically look at the care and management of related conditions (for example, rheumatoid arthritis and joint pain).

Osteoporosis

Ovarian Cancer

Pancreatic

Prostate Cancer

Rectal Cancer

  • Chemoradiation Before Surgery Helps Prevent Local Relapse of Rectal Cancer

    National Cancer Institute (Oct 2004)

    Patients with clinical stage II or stage III cancer of the rectum who received radiation and chemotherapy before surgery had fewer problems afterwards and a lower risk that their cancer would come back in the rectum, compared with patients who had radiation and chemotherapy after surgery. However, the before-surgery approach did not reduce the risk of cancer recurring elsewhere in the body or result in patients’ living any longer

Renal Cell Cancer

Respiratory tract infections

Rhrumatoid arthritis

  • "Abatacept for the treatment of rheumatoid arthritis "

    Clinicaltrials.gov (Jan 2008)

    Abatacept is not recommended for people with moderate to severe active rheumatoid arthritis who have already tried drugs known as disease-modifying anti-rheumatic drugs (including a 'TNF inhibitor'drug), which didn't work or weren't suitable. Healthcare professionals should not stop prescribing abatacept for people who were already taking it when the guidance was issued. These patients should be able to carry on taking abatacept until they and their specialist decide that it is the right time to stop treatment

  • Abatacept for the treatment of rheumatoid arthritis

    Clinicaltrials.gov (Jan 2008)

    Abatacept is not recommended for people with moderate to severe active rheumatoid arthritis who have already tried drugs known as disease-modifying anti-rheumatic drugs (including a 'TNF inhibitor'drug), which didn't work or weren't suitable. Healthcare professionals should not stop prescribing abatacept for people who were already taking it when the guidance was issued. These patients should be able to carry on taking abatacept until they and their specialist decide that it is the right time to stop treatment

Stomach Cancer

  • Adding Docetaxel Improves Survival in Stomach Cancer

    National Cancer Institute (May 2005)

    Addition of the drug docetaxel (Taxotere®) to other chemotherapy drugs used to treat advanced stomach cancer increased the number of patients surviving for at least two years. This finding offers a new treatment option for patients with this disease

  • Limited Lymph Node Removal and Stomach Cancer

    National Cancer Institute (Jun 2004)

    Long-term follow-up of patients with stomach (gastric) cancer has shown that patients treated with more extensive surgery involving the removal of more lymph nodes did not live longer than those who received a more limited lymph node removal (dissection).

  • Stomach Cancer Drug, S-1, Shows Promise in Japanese Trial

    National Cancer Institute (Mar 2008)

    In this Japanese clinical trial, patients with advanced, inoperable stomach cancer who received combination therapy with cisplatin and a drug called S-1 lived about two months longer than patients treated with S-1 alone. S-1 is not currently approved for use in the United States. Because S-1 is broken down by the body differently in patients of European and Japanese descent, many U.S. patients may not be able to tolerate the doses of the drug given in this study.

Stress

Surgical site infection

  • Prevention and treatment of surgical site infection

    NICE (Jan 2008)

    the advice in the NICE guideline covers: * adults and children who are going to have a cut through the skin for an operation. It does not specifically look at: * adults and children who are going to have an operation that does not involve a cut through the skin on the outside of the body * adults and children who are going to have procedures involving thintubes (called catheters) placed in blood vessels, tubes (called shunts) inserted into the body to divert fluid, thin flexible telescopes (called endoscopes) to view the inside of the body or metal pins used externally to treat broken bones.

Testicular Cancer

Ulcerative colitis

Uterine Sarcoma

Venous thromboembolism

Vulvar Cancer

  • Imiquimod May Help to Prevent Vulvar Cancer

    National Cancer Institute (Apr 2008)

    Women with a precancerous condition called vulvar intraepithelial neoplasia (VIN) were successfully treated with a drug that is applied to the affected areas as a cream. The drug, imiquimod (Aldara®), caused less discomfort and pain than standard surgical treatments. Although small, this study supports the conclusion that imiquimod should be the first-choice treatment for VIN.

www.hae-awareness.net is a CPD-accredited interactive training programme for physicians involved in the care and treatment of patients with hereditary angioedema Hepatitis (WHO) classifies chronic myeloid leukaemia (CML) as a myeloproliferative disease characterised by the presence of the Philadelphia chromosome (Ph) or the BCR-ABL fusion oncogene Pharmacologic management of asthma aims to control symptoms, prevent exacerbations and provide the best possible pulmonary function with minimal medications, side effects and risk factors.

Atopic Dermatitis

Atopic Dermatitis

CONNECT

DISEASE CENTRES Disease Centres feed

AFFILIATE PARTNERS

QUICK SEARCH

GUIDELINES UK Drug Data Feed

DRUG DATA UK Drug Data Feed

REFERENCES